Press Release biotechnology March 31, 2026

Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline

Blue Owl Healthcare Opportunities Redmile Deep Track Capital BVF Partners Boulder Ventures Janus Henderson Investors Samsara BioCapital Ambrosia Biosciences Inc.

Press ReleaseMarch 31, 2026

Ambrosia Biosciences Inc. has secured $100 million in an oversubscribed Series B financing to support the clinical development of its oral small molecule GLP-1 candidate and other cardiometabolic programs.

Press ReleaseMay 8, 2026

West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026

May 8, 2026

Press ReleaseMay 8, 2026

Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)

May 8, 2026

Press ReleaseMay 8, 2026

Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program

May 8, 2026

← Back to all articles

Generated by Yeal

Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline

Related articles

West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026

Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)

Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program